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Dear Editor,
In hemodialysis units, vancomycin-resistant 
Enterococcus (VRE) colonization is common, 
probably associated with vancomycin use and 
the characteristics of these patients. This pan-
orama of colonization is also found in renal 
transplant units (RTU).1 However, epidemio-
logical data including risk factors associated 
with colonization or infection due to VRE in 
this population are scanty. Here, we describe 
an outbreak and the measures used to eradicate 
VRE in a RTU.
The outbreak took place in a RTU of a 
700-bed University Hospital in Curitiba (PR, 
Brazil). The first case of VRE in this hospital was 
described in 2004 and the percentage of VRE in-
fection has been between 1.16% and 2.4%.
In March 1, 2009 the first case of VRE in the 
RTU was reported. Thus, three samples of rectal 
swabs were obtained from all patients admitted 
to the unit. Three patients turned out positive 
and one patient was negative in the first day. In 
the second week, two cases of VRE colonization 
were found and one patient had a negative cul-
ture. In the third week, one of eight patients was 
positive. In the fourth week one out of six pa-
tients was positive. Since then, no other patient 
with VRE was found in the RTU. Surveillance 
was discontinued after four months of continu-
ous vigilance. During the outbreak, a total of 
eight patients were found to be colonized and 
one patient was infected (urinary tract infec-
tion) from a total of 33 patients screened in 
the unit. Environmental samples, such as beds, 
clothes, walls, tables, chairs, doors, doorknobs, 
stretcher, mattresses, pillows, and several other 
objects were all negative. Cultures from the 
hands of healthcare workers were also negative.
Vancomycin resistance was confirmed us-
ing Kirby-Bauer disk diffusion and the E-test.2 
PCR to detect VRE resistance genes was 
performed following Petrich et al.,3 which 
amplified the vanA gene in all strains of 
Enterococcus faecium. Pulsed-field electropho-
resis, described elsewhere, demonstrated a pre-
dominant genotype.4 Genotype A and its sub-
type A1 were found in the RTU, and genotype 
B was found in patients from other units.
A case-control study was performed. Cases 
included all VRE colonized/infected patients 
from the RTU. Controls were patients with 
three rectal swabs negative for VRE admit-
ted during the same period (four months) to 
the unit. Clinical data were extracted from the 
medical records and are described in the Table 1. 
Duration of hospitalization and previous use 
of ceftriaxone were risk factors for VRE in the 
univariate analysis. Ceftriaxone was an isolated 
risk factor for VRE in the binary regression 
(p = 0.029), demonstrating an OR = 8.8 (95% 
CI: 1.25-62.20). 
An educational program about VRE was 
implemented following published guide-
lines.5 The major focus of the education pro-
gram was to enforce healthcare workers to 
adhere to contact isolation guidelines: I) wear 
of gown; II) use of gloves; III) hand hygiene 
using alcohol gel before and after any pa-
tient manipulation. Daily bath with chlorhex-
idine was done for all patients as an additional 
measure to control the outbreak. All material 
(clothes, pillows etc) used by patients were 
separated in plastic bags to further steriliza-
tion (autoclave or ethylene oxide).
Previous use of third generation cepha-
losporins was the only independent risk fac-
tor for VRE colonization in this outbreak. 
Although vancomycin has always been 
described as risk factor for VRE, third gen-
eration cephalosporins have also been nailed 
down in small series.6,7 
Costs related to VRE infection can exceed 
three times the average admission.8 In addition to 
extra cost, there is the risk of developing of an en-
demic status of VRE. In our study, intensive meas-
ures were effective to control the outbreak. The 
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Table 1. Case control study of patients colonized/infected with VRE during an outbreak
  VRE positive VRE negative p-value 
Variable (n = 9) (n = 24) 
Age (median with range) 36 (15 - 49) 37 (8 - 70) NS
Gender (male %) 55.55% 58.33% NS
Admission duration (mean ± SD) 16.11 ± 15.71 7.65 ± 3.90 0.018
DM  0.00% 4.16% NS
ICC  11.11% 4.16% NS
HAS 25.00% 33.33% NS
Intensive care unit 0.00% 4.16% NS
Surgery 11.11% 20.83% NS
Neoplasm 0.00% 0.00% NS
Under dialysis 11.11% 8.32% NS
Cyclosporine 22.22% 20.83% NS
Mophethyl-mycophenolate 100.00% 95.83% NS
Tacrolimus 77.77% 54.13% NS
Prednisone 100.00% 95.83% NS
Azathioprine 0.00% 0.00% NS
Urinary catheter 11.11% 29.16% NS
Previous renal transplant 22.22% 4.16% NS
Previous antibiotic use   
 Ceftriaxone 44.44% 8.32% 0.034
 Cefepime 11.11% 0.00% NS
 Carbapenem 0.00% 0.00% NS
 Piperacillin-tazobactam 0.00% 0.00% NS
 Vancomycin 22.22% 0.00% 0.068
 Metronidazole 0.00% 0.00% NS
 Mortality 0% 4.10% NS
NS, non-significant.
infection control activities to tackle the outbreak were extended 
to four months, a decision based on previous studies, which 
showed recurrence when carried out for only two months.9,10
Adherence to all measures of isolation and use of alcohol 
gel are enough to control a VRE outbreak, including cohort 
in larger units.11 Some authors demonstrated that even with 
all measures applied, VRE can become endemic in the hos-
pital.12 Guidelines are available but we believe that the most 
important in an outbreak is the continuous and intensive 
staff education.13 
Daily chlorhexidine bathing decreases the incidence of 
colonization by Gram-positive cocci, but its use as a meas-
ure of control of VRE outbreak has not been described. Skin 
colonization is a major source of VRE and reduction in the 
VRE acquisition rate reduces the colonization pressure.14 
This study contributes to the understanding of the 
epidemiology dynamics of a VRE outbreak in RTUs and 
highlights infection control measures that can be useful in 
the control of VRE spread. 
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